The Aplenc Lab investigates ways to improve the outcomes of children with cancer, particularly acute myeloid leukemia, through translational studies, patient-centered outcomes research, and with clinical epidemiology studies.
Your immune system is designed to protect against foreign invaders such as infections, but you may not realize that it also destroys abnormal cells that your body produces.
Dr. Grupp has received a great deal of attention for his investigation of using cell therapy to treat an aggressive form of childhood leukemia, acute lymphoblastic leukemia (ALL).
At the recent 2014 Pennsylvania Bio Annual Dinner & Awards Celebration, The Children’s Hospital of Philadelphia’s reputation as an international leader in pediatric medicine was further cemented, as the Hospital was honored with two awards celebrating its business and research innovations.
The groundbreaking immune therapy work being done by The Children's of Hospital of Philadelphia's Stephan A. Grupp, MD, PhD, was recently highlighted on Australia's 60 Minutes. The Center for Childhood Cancer Research's Director of Translational Research, Dr. Grupp has seen encouraging early results of a trial using immune therapy to treat an aggressive form of childhood leukemia, acute lymphoblastic leukemia
On its research advocacy blog Research Means Hope, the Association of American Medical Colleges (AAMC) recently highlighted an innovative immune therapy trial led by researchers from CHOP and Penn that led to the dramatic recovery of one young patient.
The innovative work being done by CHOP's Stephen Grupp, MD, was recently featured on the CBS show The Doctors. Dr. Grupp, the Center for Childhood Cancer Research's director of translational research, discussed his trial using immune therapy to treat an aggressive form of childhood leukemia, acute lymphoblastic leukemia (ALL).
